Babies born to HIV-positive mothers in Kenya face an increased risk of contracting the virus due to a shortage of critical ...

A groundbreaking Phase 1 study suggests that once-yearly intramuscular lenacapavir could be a promising option for HIV PrEP.

With the 24% cuts and PEPFAR discontinued, we estimated there could be 4.43 million to 10.75 million additional HIV ...

If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in ...

Early HIV detection can mean the difference between a long, healthy life and severe complications. Learn why timing matters ...

Researchers studied the relationship between age and the risk for skin cancer and oncovirus infections among patients with HIV.

A study published in Lancet HIV Thursday showed that patients who received gender-affirming hormones were 37% less likely to ...

The clinical trial, dubbed FRESH and conducted in Durban, South Africa, revealed that four out of 20 women with acute HIV ...

People with AIDS also have HIV, as HIV is the first stage of AIDS. Learn about the differences, how the conditions overlap, ...

HIV symptoms vary by the stage of infection, known as acute HIV infection (Stage 1), chronic HIV infection (Stage 2), and AIDS (Stage 3). During primary infection, the symptoms are caused by the virus ...

Human immunodeficiency virus, or HIV, is a virus that attacks the body’s immune system and it can lead to acquired immunodeficiency syndrome (AIDS). Currently, while there is no cure for HIV ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.